Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background.
Saved in:
| Title: | Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. |
|---|---|
| Authors: | Robinson, J.G.1, Farnier, M.2, Kastelein, J.J.3, Roth, E.M.4, Taskinen, M.R.5, Colhoun, H.M.6, Brunet, A.7, DiCioccio, A.T.8, Lecorps, G.9, Pordy, R.10, Baccara-Dinet, M.T.11, Cannon, C.P.12 |
| Source: | Atherosclerosis (00219150). Sep2016, Vol. 252, pe231-e231. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 00219150 |
|---|---|
| DOI: | 10.1016/j.atherosclerosis.2016.07.219 |
